MedTrace Logo

Real-time fMRI Neurofeedback for Mild/Moderate Depression

NCT05025904 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-08-27

No results posted yet for this study

Summary

The aim of the study is to compare the effects of the self-regulation (neurofeedback) of the fMRI signal of the prefrontal cortex in depression to ones of more conventional non-pharmacological treatment, primarily, psychotherapy.

Conditions

  • Depression Mild
  • Depression Moderate

Interventions

BEHAVIORAL

Real-time fMRI neurofeedback (rt-fMRI NFB)

Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.

BEHAVIORAL

Сognitive behavioral therapy (CBT)

A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.

BEHAVIORAL

EEG neurofeedback (EEG NFB)

EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.

Sponsors & Collaborators

  • Federal Research Center of Fundamental and Translational Medicine, Russian Federation

    lead OTHER

Principal Investigators

  • Mark B. Shtark, Ph.D. · FRC FTM

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2019-04-09
Completion
2019-04-09

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05025904 on ClinicalTrials.gov